Evaluating the effect of curcumex supplement on the symptoms of patients with COVID-19

INTERVENTION: Intervention 1: Intervention group: In the intervention group, 30 patients were treated with Curcumex, which is a combination of three ingredients (320 mg of turmeric, 150 mg of ginger, and 4 mg of black pepper) in capsule form. This drug was developed by the Department of Pharmacology of Jundishapur University of Ahvaz. this medication use twice daily, which lasts up to 30 days. During the treatment period, patients will have three visits for training and control of clinical symptoms and laboratory findings. Intervention 2: Control group: In the control group, 30 patients were treated with placebo, which was similar in appearance to the original drug. This drug was developed by the Department of Pharmacology of Jundishapur University of Ahvaz. this medication use twice daily, which lasts up to 30 days. During the treatment period, patients will have three visits for training and control of clinical symptoms and laboratory findings. CONDITION: COVID‐19. ; COVID‐19, virus identified U07.1 PRIMARY OUTCOME: Investigation of the improvement rate of clinical symptoms of patients including cough, dyspnea, weakness, fever and diarrhea one month after take medication. Timepoint: At the beginning of the study and one month later. Method of measurement: history and physical examination. SECONDARY OUTCOME: Comparison of the effect of Curcume Xtreatment on changes in liver enzymes. Timepoint: At the beginning of the study and after 30 days from the start of taking medication. Method of measurement: lab data. Comparison of the effect of Curcume Xtreatment on changes in serum creatinine. Timepoint: At the beginning of the study and after 30 days from the start of taking medication. Method of measurement: lab data. CRP. Timepoint: At the beginning of the study and after 30 days from the start of taking medication. Method of measurement: lab data. ESR. Timepoint: At the beginning of the study and after 30 days from the start of taking medication. Method of measurement: lab data. White blood cell counts. Timepoint: At the beginning of the study and after 30 days from the start of taking medication. Method of measurement: lab data. INCLUSION CRITERIA: ground glass opacity in lung CT scan Clinical symptoms such as dry cough‐ dyspnea‐fever‐ weakness‐ diarrhea‐ headache‐rhinorrhea‐ or history of contact with COVID19 patient or recent travel to high‐risk areas Positive Covid‐19PCR